Is Sermorelin Legal in New York? How to Access It Legally
Key numbers
- 30 micrograms per kgStudy dose of sermorelin used in the pivotal pediatric program, once daily subcutaneously at bedtime; not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 14 daysDuration of the study in older men that used 0.5 mg or 1 mg sermorelin twice daily; a study dose, not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 0.05 mgGeref strength per ampule under NDA 019863, approved for testing the pituitary's growth hormone secretionSource: federalregister.gov, as cited Nov 7, 2026
See the public record for Sermorelin
At a glance
- FDA-approved today / No — Geref's approvals were withdrawn in 2009 [1]
- Drug class / GHRH analogue; prompts the pituitary to release growth hormone [3]
- What is sold now / Compounded, not FDA-approved [2]
- FDA safety-risk bulk list / Sermorelin is not listed [4]
- Outsourcing-facility nominations / Category 1, under evaluation [5]
- State-pharmacy bulk list / Sermorelin appears in no category [6]
- Sport / Prohibited at all times by WADA, S2.2.4 [7]
What is sermorelin's legal status today?
Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone; it prompts the pituitary to release the body's own growth hormone and is not growth hormone itself [3]. Its effect is rapid and short-lived: after an intravenous dose in healthy men, sermorelin was eliminated quickly, yet growth hormone stayed raised for about three hours [8].
No sermorelin product is FDA-approved today. Geref was discontinued in 2008, and FDA withdrew its approvals effective June 18, 2009 [1]. What is sold now is compounded, and compounded drugs are not FDA-approved [2].
HealthRX.com offers sermorelin by prescription.
Questions worth asking
What happened to Geref?
Geref existed under two applications [1]: NDA 019863, 0.05 mg per ampule, approved December 28, 1990, for evaluating the pituitary's ability to secrete growth hormone; and NDA 020443, 0.5 mg and 1 mg vials, approved September 26, 1997, for treating idiopathic growth hormone deficiency in children with growth failure. The manufacturer discontinued both and asked FDA to withdraw them; in March 2013 FDA determined Geref was not withdrawn for reasons of safety or effectiveness [1][9]. Its approved uses were only that pediatric treatment and the diagnostic test — not adults, anti-aging, weight loss or athletic performance [1].
What do FDA's compounding lists say?
- Safety-risk list: sermorelin is not among the bulk substances FDA has flagged as possibly presenting significant safety risks (content dated 04/22/2026) [4].
- Outsourcing facilities: on the list updated March 21, 2025, sermorelin acetate is in category 1 (under evaluation) and carries the symbol for substances that are components of FDA-approved drugs [5].
- State-licensed pharmacies and physicians: sermorelin appears in no category on the list updated May 14, 2026 [6], and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [10].
Can athletes use it?
No — WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, alongside CJC-1293, CJC-1295 and tesamorelin, and prohibits it at all times, in and out of competition [7]. The 2027 List, in force January 1, 2027, also names it [11].
What doses have been studied?
No sermorelin product is currently FDA-approved, so there is no current FDA-approved dose. The pivotal pediatric program used 30 micrograms per kg once daily subcutaneously at bedtime, and a study in older men used 0.5 mg or 1 mg twice daily for 14 days; those are study doses, not recommended doses [12][13].
Frequently asked questions
Is sermorelin legal in New York?
Was sermorelin ever FDA-approved?
Is sermorelin banned in sport?
Does FDA treat sermorelin as a compounding safety risk?
References
Show all 13 referencesHide references
- Federal Register :: Request Access.
- Official web page.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-5.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.